Differential antiproliferative effects of calcitriol on tumor-derived and Matrigel-derived endothelial cells

Cancer Research

Volumn 66, Issue 17, 2006, Pages 8565-8573

  Chung, Ivy ^a   Wong, Michael K ^a   Flynn, Geraldine ^a   Yu, Wei Dong ^a   Johnson, Candace S ^a   Trump, Donald L ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CASPASE 3; LIPOCORTIN 5; MATRIGEL; MITOGEN ACTIVATED PROTEIN KINASE; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; VITAMIN D RECEPTOR;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA SYNTHESIS; DOWN REGULATION; DRUG EFFECT; ENDOTHELIUM CELL; LIGAND BINDING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCATCHARD PLOT; SQUAMOUS CELL CARCINOMA;

ANIMALS; CALCITRIOL; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL DIVISION; CELL NUCLEUS; COLLAGEN; DNA PRIMERS; DRUG COMBINATIONS; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTORS; HUMANS; LAMININ; MICE; MICE, INBRED C3H; NEOPLASM INVASIVENESS; PROTEOGLYCANS; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 33749039210     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0905     Document Type: Article

References (50)

1. DeLuca HF, Schnoes HK. Vitamin D: recent advances. Annu Rev Biochem 1983;52:411-39.
2. Pols HA, Birkenhager JC, Foekens JA, van Leeuwen JP. Vitamin D: a modulator of cell proliferation and differentiation. J Steroid Biochem Mol Biol 1990;37:873-6.
3. Lokeshwar BL, Schwartz GG, Selzer MG, et al. Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089. Cancer Epidemiol Biomarkers Prev 1999;8:241-8.
4. Welsh J. Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens. Biochem Cell Biol 1994;72:537-45.
5. 3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. Cancer Res 2000;60:2304-12.
6. 3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo. Cancer Res 1999;59:2644-9.
7. 3: in vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treat Rep 1985;69:1399-407.
8. 1 accumulation. Endocrinology 1998;139:1197-207.
9. 3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin. J Mol Endocrinol 1997;19:15-27.
10. Bernardi RJ, Johnson CS, Modzelewski RA, Trump DL. Antiproliferative effects of 1α,25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells. Endocrinology 2002;143:2508-14.
11. 3. Studies in cultured bovine aortic endothelial cells and human dermal capillaries. J Clin Invest 1989;83:1903-15.
12. Dimitroff CJ, Klohs W, Sharma A, et al. Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy. Invest New Drugs 1999;17:121-35.
13. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;390:404-7.
14. 3 analogues. Eur J Pharmacol 1990;178:247-50.
15. Shokravi MT, Marcus DM, Alroy J, Egan K, Saornil MA, Albert DM. Vitamin D inhibits angiogenesis in transgenic murine retinoblastoma. Invest Ophthalmol Vis Sci 1995;36:83-7.
16. 3 of colon carcinogenesis induced by azoxymethane in Wistar rats. Int J Cancer 1999;81:730-3.
17. Masood R, Nagpal S, Zheng T, et al. Kaposi sarcoma is a therapeutic target for vitamin D(3) receptor agonist. Blood 2000;96:3188-94.
18. Zehnder D, Bland R, Chana RS, et al. Synthesis of 1,25-dihydroxyvitamin D(3) by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion. J Am Soc Nephrol 2002;13:621-9.
19. Hashizume H, Baluk P, Morikawa S, et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000;156:1363-80.
20. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005;15:102-11.
21. Giuliani N, Colla S, Rizzoli V. Angiogenic switch in multiple myeloma. Hematology 2004;9:377-81.
22. Folkman J, Haudenschild CC, Zetter BR. Long-term culture of capillary endothelial cells. Proc Natl Acad Sci U S A 1979;76:5217-21.
23. Modzelewski RA, Davies P, Watkins SC, Auerbach R, Chang MJ, Johnson CS. Isolation and identification of fresh tumor-derived endothelial cells from a murine RIF-1 fibrosarcoma. Cancer Res 1994;54:336-9.
24. Brown CK, Modzelewski RA, Johnson CS, Wong MK. A novel approach for the identification of unique tumor vasculature binding peptides using an E. coli peptide display library. Ann Surg Oncol 2000;7:743-9.
25. Passaniti A, Taylor RM, Pili R, et al. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest 1992;67:519-28.
26. Hida K, Hida Y, Amin DN, et al. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res 2004;64:8249-55.
27. Nakajima Y, Miyake S, Tanaka K, et al. The expressions of p21 and pRB may be good indicators for the sensitivity of esophageal squamous cell cancers to CPT-11: Cell proliferation activity correlates with the effect of CPT-11. Cancer Sci 2004;95:464-8.
28. Lee SO, Nadiminty N, Wu XX, et al. Selenium disrupts estrogen signaling by altering estrogen receptor expression and ligand binding in human breast cancer cells. Cancer Res 2005;65:3487-92.
29. Jin H, Aiyer A, Su J, et al. A homing mechanism for bone marrow-derived progenitor cell recruitment to the neovasculature. J Clin Invest 2006;116:652-62.
30. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
31. Ribatti D. The involvement of endothelial progenitor cells in tumor angiogenesis. J Cell Mol Med 2004;8:294-300.
32. Varet J, Vincent L, Akwa Y, et al. Dose-dependent effect of dehydroepiandrosterone, but not of its sulphate ester, on angiogenesis. Eur J Pharmacol 2004;502:21-30.
33. Donate F, Juarez JC, Guan X, et al. Peptides derived from the histidine-proline domain of the histidine-proline-rich glycoprotein bind to tropomyosin and have antiangiogenic and antitumor activities. Cancer Res 2004;64:5812-7.
34. Wong RJ, Chan MK, Yu Z, et al. Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12. Clin Cancer Res 2004;10:4509-16.
35. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 2002;160:985-1000.
36. Chang MJ, Modzelewski RA, Russell DM, Johnson CS. Interleukin 1α and γ-interferon induction of nitric oxide production from murine tumor-derived endothelial cells. Cancer Res 1996;56:886-91.
37. 3 receptor on growth-regulatory pathways in mammary gland and breast cancer. J Steroid Biochem Mol Biol 2002;83:85-92.
38. 3-mediated antitumor activity with dexamethasone. J Natl Cancer Inst 1998;90:134-41.
39. Adams JS, Chen H, Chun R, et al. Response element binding proteins and intracellular vitamin D binding proteins: novel regulators of vitamin D trafficking, action and metabolism. J Steroid Biochem Mol Biol 2004;89-90:461-5.
40. 3-modulated heterodimer. J Biol Chem 1991;266:23296-305.
41. Tagami T, Lutz WH, Kumar R, Jameson JL. The interaction of the vitamin D receptor with nuclear receptor corepressors and coactivators. Biochem Biophys Res Commun 1998;253:358-63.
42. Carlberg C, Saurat JH. Vitamin D-retinoid association: molecular basis and clinical applications. J Investig Dermatol Symp Proc 1996;1:82-6.
43. 3 24-hydroxylase. FEBS Lett 1991;278:195-8.
44. 3 in DU145 human prostate cancer cells: role of the direct inhibition of CYP24 enzyme activity. Mol Cell Endocrinol 2005;241:49-61.
45. 3 in seven human prostatic carcinoma cell lines. Clin Cancer Res 1995;1:997-1003.
46. Oda Y, Sihlbom C, Chalkley RJ, et al. Two distinct coactivators, DRIP/mediator and SRC/p160, are differentially involved in vitamin D receptor transactivation during keratinocyte differentiation. Mol Endocrinol 2003;17:2329-39.
47. Kato S, Fujiki R, Kitagawa H. Vitamin D receptor (VDR) promoter targeting through a novel chromatin remodeling complex. J Steroid Biochem Mol Biol 2004;89-90:173-8.
48. Spencer TE, Jenster G, Burcin MM, et al. Steroid receptor coactivator-1 is a histone acetyltransferase. Nature 1997;389:194-8.
49. Nagy L, Kao HY, Chakravarti D, et al. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 1997;89:373-80.
50. Lewis JS, Jordan VC. Selective estrogen receptor modulators (SERMs): Mechanisms of anticarcinogenesis and drug resistance. Mutat Res 2005;591:247-63.